Christie Charity

Christie Charity is the dedicated fundraising arm of The Christie NHS Foundation Trust, Europe's largest single-site cancer centre in Manchester, rooted in the 1890 legacy of Richard Copley Christie and Mary Christie. Established to advance cancer prevention, treatment, research, education, and patient care beyond core NHS funding, it embodies values of excellence, innovation, compassion, and public benefit. With independent governance including Trust and community trustees, it raised over £17 million recently, channeling resources into transformative projects like proton beam therapy, advanced radiotherapy, the Paterson Research Building, Maggie’s Centre, and the Young Oncology Unit for teenagers and young adults.

It prioritizes cancer-related initiatives enhancing patient experience, family support, clinical facilities, pioneering research via partnerships like the Manchester Cancer Research Centre and Cancer Research UK Manchester Institute, staff training through the Christie School of Oncology, and state-of-the-art equipment. Beneficiaries are primarily cancer patients, carers, and oncology professionals at The Christie, with funding favoring large-scale capital projects, service innovations, and research breakthroughs offering national impact.

Unsolicited applications are not accepted; eligibility is limited to The Christie NHS Foundation Trust and select aligned partners, with a geographic focus on Greater Manchester and Cheshire, though projects with broader UK relevance qualify. No income thresholds or entity types are specified for externals, as decisions are internal via the Board of Trustees without fixed deadlines or public processes. Typical grants are undisclosed but include multi-million-pound investments for major initiatives; it excludes core costs, unrestricted funding, emergency relief, and general external charity requests.

Distinctively, Christie Charity's tight integration with a world-leading NHS specialist hospital ensures laser-focused impact on cancer outcomes, differentiating it as a partner-driven funder plugging statutory gaps rather than an open grantmaker.